AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22422428 — intervention group
Group type: COMPARATOR
Intervention: Conventional Geriatric Care (non-CGU)
Number of subjects: 96
Study 19228235 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support for cancer survivors and families
Number of subjects: 0
Study 19228235 — intervention group
Group type: EXPERIMENTAL
Intervention: General well-being support for families
Number of subjects: 0
Study 17488660 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 1.0-4.2 mg/kg
Number of subjects: 64
Study 17488660 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 2.0-8.0 mg/kg
Number of subjects: 64
Study 17488660 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A.
Number of subjects: 64
Study 15015070 — intervention group
Group type: EXPERIMENTAL
Intervention: IVCP (500 mg/m² per month IV for 6 months)
Number of subjects: 47
Study 15015070 — intervention group
Group type: COMPARATOR
Intervention: OCP (2 mg/kg per day for 12 weeks)
Number of subjects: 47
Study 11235791 — intervention group
Group type: EXPERIMENTAL
Intervention: Volvo 'WHIPS' seat
Number of subjects: 3
Study 11235791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic seat test
Number of subjects: 3
Study 11235791 — intervention group
Group type: COMPARATOR
Intervention: Seat properties (geometry, stiffness, energy absorption)
Number of subjects: 3
Study 9678536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bororos
Number of subjects: 0
Study 9678536 — intervention group
Group type: COMPARATOR
Intervention: Rural people
Number of subjects: 0
Study 9678536 — intervention group
Group type: COMPARATOR
Intervention: Italian population
Number of subjects: 0
Study 7850992 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoresis method for detecting Lp(a)
Number of subjects: 719
Study 7850992 — intervention group
Group type: COMPARATOR
Intervention: Electroimmunoassay for Lp(a)
Number of subjects: 719
Study 3289737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/m2 monoclonal anti-carcinoembryonic antigen (CEA) antibody, NP-2, administered three times weekly or once a week for 12 to 240 days (5 to 13 injections)
Number of subjects: 10
Study 3289737 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking radioimmunoassay using [125I]NP-2-F(ab')2
Number of subjects: 10
Study 3289737 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal studies
Number of subjects: 10
Study 28478985 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride paste (group P)
Number of subjects: 67
Study 28478985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord and aluminum chloride paste (group CP)
Number of subjects: 67
Study 28478985 — intervention group
Group type: COMPARATOR
Intervention: Double-cord technique (group C)
Number of subjects: 67
Study 27461451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise with private consultations, educational DVDs and pamphlets
Number of subjects: 52
Study 27461451 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care (Control)
Number of subjects: 52
Study 25247728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive/affective/behavioral intervention involving college swim team members working with 8 Special Olympics swimmers over 4 sessions in 6 weeks.
Number of subjects: 33
Study 25247728 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (N = 17).
Number of subjects: 33
Study 22795879 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal Cone (TM Cone)
Number of subjects: 40
Study 22795879 — intervention group
Group type: COMPARATOR
Intervention: No TM Cone
Number of subjects: 40
Study 22795879 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TM Cone and No TM Cone)
Number of subjects: 40
Study 22795879 — intervention group
Group type: EXPERIMENTAL
Intervention: TM Cone
Number of subjects: 40
Study 20601412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg) daily for 6 months
Number of subjects: 30
Study 20601412 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel daily for 6 months
Number of subjects: 30
Study 18694901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (13.2 to 39.0 mug/kg per day in 3 divided doses)
Number of subjects: 26
Study 18694901 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care oral neonatal opium solution
Number of subjects: 26
Study 18694901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 26
Study 15919772 — intervention group
Group type: EXPERIMENTAL
Intervention: SR misoprostol 800 microg
Number of subjects: 30
Study 15919772 — intervention group
Group type: COMPARATOR
Intervention: Conventional misoprostol 400 microg
Number of subjects: 30
Study 15919772 — intervention group
Group type: COMPARATOR
Intervention: SR misoprostol 400 microg
Number of subjects: 30
Study 12612897 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX-4016 (400 and 800 mg twice daily)
Number of subjects: 40
Study 12612897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (200 and 420 mg twice daily)
Number of subjects: 40
Study 12612897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10234582 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) and calcium carbonate (500 mg/day)
Number of subjects: 26
Study 10234582 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 26
Study 8690689 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilty participants who received countermeasure instructions
Number of subjects: 4
Study 8690689 — intervention group
Group type: EXPERIMENTAL
Intervention: Guilty participants who received countermeasure instructions and were allowed to practice the countermeasures
Number of subjects: 4
Study 8690689 — intervention group
Group type: COMPARATOR
Intervention: Guilty controls who committed the mock crime but received no countermeasure instructions
Number of subjects: 4
Study 8690689 — intervention group
Group type: COMPARATOR
Intervention: Innocent participants who were not involved in the mock crime
Number of subjects: 4
Study 8315230 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 135
Study 8315230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercise
Number of subjects: 135
Study 8315230 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 3826200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine transdermal therapeutic system
Number of subjects: 29
Study 3826200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30460981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous haloperidol (0.5 mg three times daily for a total of 11 doses)
Number of subjects: 135
Study 30460981 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous haloperidol (0.5 mg three times daily for a total of 11 doses) in esophagectomy subgroup
Number of subjects: 135
Study 28550338 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transcanalicular dacryocystorhinostomy (MT-DCR)
Number of subjects: 44
Study 28550338 — intervention group
Group type: COMPARATOR
Intervention: Conventional transcanalicular dacryocystorhinostomy (T-DCR)
Number of subjects: 44
Study 25804628 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centered diabetes self-management education (DSME) in the emergency department.
Number of subjects: 0
Study 23910226 — intervention group
Group type: EXPERIMENTAL
Intervention: CBC-based prognostic index
Number of subjects: 3237
Study 23910226 — intervention group
Group type: COMPARATOR
Intervention: TNM system
Number of subjects: 3237
Study 21989186 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFOX4
Number of subjects: 1106
Study 21989186 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFIRI
Number of subjects: 1106
Study 21989186 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 1106
Study 21989186 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 1106
Study 19341446 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg intradermal vaccine
Number of subjects: 1150
Study 19341446 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 microg intradermal vaccine
Number of subjects: 1150
Study 19341446 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 microg intradermal vaccine
Number of subjects: 1150
Study 19341446 — intervention group
Group type: COMPARATOR
Intervention: 15 microg intramuscular vaccine
Number of subjects: 1150
Study 19341446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and intradermal vaccinations
Number of subjects: 1150
Study 17014279 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cancer prevention intervention
Number of subjects: 1788
Study 12969534 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy (AF group, n=138, 6 fractions per week, 180‐190 cGy per day, total dose 7,400‐7,600 cGy)
Number of subjects: 416
Study 12969534 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy with concurrent chemotherapy (AFC group, n=139, 6 fractions per week, 180‐190 cGy per day, total dose 7,400‐7,600 cGy, cisplatin and 5‐FU one time per week)
Number of subjects: 416
Study 12969534 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CF group, n=139, 5 fractions per week, 200 cGy per day, total dose 7,000‐7,600 cGy)
Number of subjects: 416
Study 10935809 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen cultured human allogeneic epidermal sheets
Number of subjects: 11
Study 10935809 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-coated gauze (control)
Number of subjects: 11
Study 8944932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis dose (KprT/V) ranging from 1.5 to 2.3
Number of subjects: 0
Study 8944932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with (KprT/V)ud = 2.00
Number of subjects: 0
Study 8944932 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted decrease in renal urea clearance (KrT/V)
Number of subjects: 0
Study 8944932 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum (KprT/V)ud level achieved in CANUSA
Number of subjects: 0
Study 1683559 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms ropinirole preceded by 20 mg domperidone
Number of subjects: 9
Study 1683559 — intervention group
Group type: COMPARATOR
Intervention: 800 micrograms ropinirole
Number of subjects: 9
Study 1683559 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg domperidone
Number of subjects: 9
Study 1683559 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg domperidone followed by ropinirole-placebo
Number of subjects: 9
Study 7202230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet plus benztropine mesylate
Number of subjects: 29
Study 7202230 — intervention group
Group type: COMPARATOR
Intervention: Sinemet plus placebo
Number of subjects: 29
Study 31475296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (target dosage, 97/103 mg twice daily)
Number of subjects: 464
Study 31475296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 464
Study 31475296 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (target dosage, 10 mg twice daily)
Number of subjects: 464
Study 31475296 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 464
Study 28662338 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' relationship enrichment program (5 sessions)
Number of subjects: 80
Study 28662338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 25752834 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment (single infusion)
Number of subjects: 0
Study 25752834 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 0
Study 23339809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence within the first month
Number of subjects: 2997
Study 23339809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence during 1-6 months
Number of subjects: 2997
Study 23339809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence during 6-12 months
Number of subjects: 2997
Study 23339809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) adherence beyond one year
Number of subjects: 2997
Study 20869329 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass
Number of subjects: 44
Study 19919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) 150-300 mg
Number of subjects: 24
Study 19919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) 21 mg
Number of subjects: 24
Study 19919396 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion combined with transdermal nicotine (BUP+TN)
Number of subjects: 24
Study 19919396 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - no drugs
Number of subjects: 24
Study 19919396 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PL)
Number of subjects: 24
Study 16890574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg twice daily for 2 days)
Number of subjects: 20
Study 16890574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16890574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 20
Study 15310632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%, N(2)O 67% and iv remifentanil 1 to 1.5 microg.kg(‐1)
Number of subjects: 156
Study 15310632 — intervention group
Group type: COMPARATOR
Intervention: iv fentanyl 2 to 3 microg.kg(‐1), propofol 2 mg.kg(‐1), and rocuronium 0.3 to 0.5 mg.kg(‐1)
Number of subjects: 156
Study 15310632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane‐remifentanil induction
Number of subjects: 156
Study 11742191 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (6, 9, or 18 mg daily)
Number of subjects: 318
Study 11742191 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroid pretreatment)
Number of subjects: 318
Study 9204361 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque 350)
Number of subjects: 82
Study 9204361 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate (Isopaque Coronar 370)
Number of subjects: 82
Study 8052507 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kgbw Biltricide (Group 1)
Number of subjects: 35
Study 8052507 — intervention group
Group type: COMPARATOR
Intervention: 40 mg/kgbw (Group 2) - 12 Biltricide, 10 Distocide
Number of subjects: 35
Study 3148130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbaryl lotion
Number of subjects: 268
Study 3148130 — intervention group
Group type: EXPERIMENTAL
Intervention: Malathion solution
Number of subjects: 268
Study 3148130 — intervention group
Group type: COMPARATOR
Intervention: Pyrethrin shampoo
Number of subjects: 268
Study 3148130 — intervention group
Group type: COMPARATOR
Intervention: Pyrethroid spray
Number of subjects: 268
Study 3148130 — intervention group
Group type: COMPARATOR
Intervention: Carbaryl shampoo
Number of subjects: 268
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 8 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 16 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 32 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 24 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 48 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 72 mg
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar 16 mg (multiple doses)
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar with food
Number of subjects: 0
Study 31037611 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar (overall)
Number of subjects: 0
Study 28159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised centre-based exercise rehabilitation
Number of subjects: 158
Study 28159358 — intervention group
Group type: COMPARATOR
Intervention: Self-management home-based exercise rehabilitation
Number of subjects: 158
Study 28159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based setting preference
Number of subjects: 158
Study 28159358 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression score in Hospital Anxiety and Depression Score
Number of subjects: 158
Study 26509793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) for 12 weeks (n = 13)
Number of subjects: 28
Study 26509793 — intervention group
Group type: COMPARATOR
Intervention: No Lactobacillus casei Shirota (no LcS) (n = 15)
Number of subjects: 28
Study 26509793 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 16)
Number of subjects: 28
Study 23389073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Simulation Unit (MSU) training on LapSim
Number of subjects: 144
Study 23389073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Simulation Unit (MSU) training on FLS
Number of subjects: 144
Study 23389073 — intervention group
Group type: COMPARATOR
Intervention: Fixed-site training on LapSim
Number of subjects: 144
Study 23389073 — intervention group
Group type: COMPARATOR
Intervention: Fixed-site training on FLS
Number of subjects: 144
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-platform-switched implants
Number of subjects: 9
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant platform 4.3 mm
Number of subjects: 9
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant platform 4.8 mm
Number of subjects: 9
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant platform 5.5 mm
Number of subjects: 9
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with biglycans
Number of subjects: 9
Study 21691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with tumor necrosis factor-a
Number of subjects: 9
Study 17585313 — intervention group
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium (0.3, 1, and 3 mg)
Number of subjects: 569
Study 17585313 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 569
Study 16939029 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Etch + Syntac Single Component
Number of subjects: 3
Study 16939029 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntac Single Component
Number of subjects: 3
Study 16939029 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 3
Study 12904090 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0
Study 10714832 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic tube compensation (ATC)
Number of subjects: 10
Study 10714832 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 10
Study 10714832 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV) with immediate pressure rise
Number of subjects: 10
Study 10714832 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV) with delayed pressure rise
Number of subjects: 10
Study 9185468 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 50 mg flurbiprofen with standardized general anesthesia
Number of subjects: 60
Study 9185468 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anesthesia (control group)
Number of subjects: 60
Study 9185468 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional combined epidural and general anesthesia with epidural administration of 0.25% bupivacaine 5‐8 ml and 0.1‐0.2 mg buprenorphine after surgery
Number of subjects: 60
Study 1489039 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 0
Study 1489039 — intervention group
Group type: COMPARATOR
Intervention: Dorsal nerve block
Number of subjects: 0
Study 3516409 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg daily)
Number of subjects: 29
Study 3516409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29722747 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic natural progesterone therapy
Number of subjects: 0
Study 29722747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27942208 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 µg)/salbutamol (2.5 mg)
Number of subjects: 40
Study 27942208 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 24297940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (3,000 mg/m2 every 12 hours by 3-hour infusion on days 1, 3, 5, and 7)
Number of subjects: 1942
Study 24297940 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine (100 mg/m2 per day by continuous infusion for 10 days)
Number of subjects: 1942
Study 22735285 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable pin fixation
Number of subjects: 100
Study 22735285 — intervention group
Group type: COMPARATOR
Intervention: No fixation
Number of subjects: 100
Study 22735285 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cast
Number of subjects: 100
Study 22735285 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 100
Study 22735285 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative angles over 30 degrees
Number of subjects: 100
Study 21395141 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation with 0.2% Prismocitrate 10/2 solution
Number of subjects: 38
Study 17478491 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g i.v.) for 4 months
Number of subjects: 10
Study 17478491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g i.v.) for 4 months
Number of subjects: 10
Study 17478491 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (first 4 months) followed by L-carnitine (2 g i.v.) for 4 months
Number of subjects: 10
Study 17478491 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (0.5 mM and 5 mM) pre-incubation before agonist stimulation
Number of subjects: 10